Bibliography
- Buse JB, Drucker DJ, Taylor KL, for the DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57
- Edwards CM, Stanley SA, Davis R, Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-61
- Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin- 4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88
- Buse JB, Henry RR, Han J, Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
- DeFronzo RA, Ratner RE, Han J, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
- Kendall DM, Riddle MC, Rosenstock J, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
- Zinman B, Hoogwerf BJ, Duran Garcia S, The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85
- Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001;24:1416-21
- Zander M, Madsbad S, Madsen JL, Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
- Drucker DJ, Buse JB, Taylor K, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
- Kim D, MacConell L, Zhuang D, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. diabetes care 2007;30:1487-93
- Tracy MA, Ward KL, Firouzabadian L, Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999;20:1057-62
- BYETTA prescribing information [article online], 2006. Available from: http://pi. lilly.com/us/byetta-pi.pdf. Accessed 5 September 2006
- Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40
- Kendall DM, Riddle MC, Rosenstock J, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
- Barnett AH, Burger J, Johns D, Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-48
- Heine RJ, Van Gaal LF, Johns D, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
- Nauck MA, Duran S, Kim D, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: non-inferiority study. Diabetologia 2007;50:259-67